3 beaten-up shares that could be worth another look in 2017

Over the past 12 months, the S&P/ASX 200 (Index: ^AXJO) (ASX:XJO) has rallied nearly 13% according to Google Finance – and that is excluding dividends!

Most investors would be fairly pleased with this result, especially those who have held resources shares during this time.

Unfortunately, a number of non-mining related shares have struggled over the past 12 months and this has put a handbrake on the returns of those investors who have been underweight the resources sector.

Despite this, I think now may be a good time for investors to take another look at some of these beaten-up shares, including:

Mayne Pharma Group Ltd (ASX: MYX)

Mayne Pharma delivered a spectacular increase in profits in its latest first-half earnings result, but still remains a high-risk, high-reward proposition as a result of the uncertainty created by a U.S. investigation into price fixing of drugs. The company has played down the claims so far and has reiterated a positive growth outlook on the back of a large pipeline of new products and cost synergies. While this is a stock risk-averse investors should avoid right now, I think investors who are comfortable with volatility should take a closer look at the drug maker considering the shares are trading on a historically low earnings multiple.

Freelancer Ltd (ASX: FLN)

The Freelancer share price has lost more than 50% of its value since July 2016, mainly on the back of disappointing results from its recently acquired business. On a more positive note, the company’s core business continues to perform strongly and has grown its registered user base over the past 12 months by 26% to 23.3 million people. Pleasingly, Freelancer is now delivering positive operating cashflow and is still well positioned to take advantage of the shifting trends impacting the global workforce.

Nearmap Ltd (ASX: NEA)

The Nearmap share price has fallen more than 40% from its 52-week highs, largely on the back of slower-than-expected progress in the lucrative U.S. aerial imaging market. While progress has been slower-than-expected, the company is beginning to show signs of improvement with the number of customers and value of contracts increasing significantly in the first half of FY17. While Nearmap is still considered a speculative share at this stage, I think the company’s current valuation represents an attractive value proposition, especially if Nearmap can gain traction in North America.

If you hate speculative shares, then you might want to consider these Top 3 ASX Blue Chips To Buy In 2017

For many, blue chip stocks means stability, profitability and regular dividends, often full franked..

But knowing which blue chips to buy, and when, can often be fraught with danger.

The Motley Fool's in-house analyst team has poured over thousands of hours worth of proprietary research to bring you the names of "The Motley Fool's Top 3 Blue Chip Stocks for 2017."

Each one pays a fully franked dividend. Each one has not only grown its profits, but has also grown its dividend. One increased it by a whopping 33%, while another trades on a grossed up (fully franked) dividend yield of almost 7%.

If you're expecting to see the likes of Commonwealth Bank, Telstra and Wesfarmers shares on this list, you'll be sorely disappointed. Not only are their dividends growing at a snail's pace, their profits are under pressure too due to the increasing competitive environment.

The contrast to these "new breed" blue chips couldn't be greater... especially the very real prospect of significant share price gains, something that's looking less likely from the usual blue chip suspects.

The names of these Top 3 ASX Blue Chips are included in this specially prepared free report. But you will have to hurry. Depending on demand - and how quickly the share prices of these companies moves - we may be forced to remove this report.

Click here to claim your free report.

Motley Fool contributor Christopher Georges owns shares of Mayne Pharma Group Limited. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

Two New Stock Picks Every Month!

Not to alarm you, but you’re about to miss a very important event! Chief Investment Advisor Scott Phillips and his team at Motley Fool Share Advisor are about to reveal their latest official stock recommendation. The premium “buy alert” will be unveiled to members and you can be among the first to act on the tip.

Don’t let this opportunity pass you by – this is your chance to get in early!

Simply enter your email now to find out how you can get instant access.

By clicking this button, you agree to our Terms of Service and Privacy Policy. We will use your email address only to keep you informed about updates to our website and about other products and services we think might interest you. You can unsubscribe from Take Stock at anytime. Please refer to our Financial Services Guide (FSG) for more information.